Home Biochemistry of B-type natriuretic peptide – where are we now?
Article
Licensed
Unlicensed Requires Authentication

Biochemistry of B-type natriuretic peptide – where are we now?

  • Johannes Mair
Published/Copyright: October 9, 2008

Abstract

Background: The discovery of the cardiac endocrine function more than 25 years ago was a breakthrough for the implementation of a routine laboratory marker of heart failure. The heart secretes two different natriuretic peptides with similar biological effects. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) emerged as the superior diagnostic markers compared to circulating A-type natriuretic peptide (ANP) and proANP derived peptide forms. However, the biochemistry with the processing and metabolism of proBNP, NT-proBNP and BNP with their impact on BNP quantification are still incompletely understood.

Methods: Published data and own results were used.

Results: This review shows that the present understanding of the biochemistry of BNP and its circulating forms is far from complete. The regulation of BNP secretion occurs mainly at the level of gene transcription with only minor stores of proBNP and processed BNP 1–32 within cardiomyocytes. proBNP is believed to be split into BNP 1–32 and NT-proBNP 1–76 mainly upon secretion, although limited amounts of processed BNP have also been described in the secretory granules of atrial cardiomyocytes. proBNP can be also detected in the circulation and exists as a monomer. There is no evidence for relevant processing of proBNP into BNP 1–32 and NT-proBNP in the circulation. Only small amounts of the intact hormone BNP 1–32 appear to circulate in plasma, there are no known BNP binding proteins. The major circulating BNP forms appear to be split products of BNP 1–32, but are still not sufficiently characterized. Dipeptidyl-peptidase IV degrades BNP 1–32 to BNP 3–32 at its N-terminal end. NT-proBNP appears to be rapidly truncated at both ends as well. proBNP and NT-proBNP are glycosylated to a variable degree. BNP and NT-proBNP are extracted by the kidneys to a comparable extent. In contrast to BNP, the biological half-life of NT-proBNP in humans is still not known. The current commercial BNP assays do not significantly cross-react with NT-proBNP and vice versa. However, BNP as well as NT-proBNP assays cross-react with proBNP to a varying extent.

Conclusions: The better characterization of circulating proBNP, BNP, and NT-proBNP forms is necessary to define the relevant standard for assay standardization. Until then, assays should be designed to detect the total amount of the circulating analyte to achieve optimal sensitivity. The identification of possible disease effects on proBNP, BNP, and NT-proBNP metabolism could pave the way for the development of more disease specific assays in the clinical setting.

Clin Chem Lab Med 2008;46:1507–14.


Corresponding author: Johannes Mair, MD, Universitätsklinik fuer Innere Medizin III, Kardiologie, Anichstrasse 35, 6020 Innsbruck, Austria Phone: +512-504-81314, Fax: +512-504-22767,

Received: 2008-5-31
Accepted: 2008-8-20
Published Online: 2008-10-9
Published in Print: 2008-11-01

©2008 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Biochemical markers in clinical cardiology: perspectives from present to future. 1st IFCC-Ortho Clinical Diagnostics Conference on Clinical Diagnosis and the Clinical Laboratory
  3. Highlight: Cardiovascular Biomarkers
  4. Reviews
  5. The clinical impact of the universal diagnosis of myocardial infarction
  6. Troponin revisited 2008: assay performance
  7. Standardization of troponin I measurements: an update
  8. Biochemistry of B-type natriuretic peptide – where are we now?
  9. Clinical relevance of non-cardiac determinants of natriuretic peptide levels
  10. What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care?
  11. Natriuretic peptide testing in primary care patients
  12. Natriuretic peptide testing in emergency settings
  13. Minireviews
  14. Oxidative stress, free radicals and bone remodeling
  15. Plasma homocysteine and vascular disease in elderly patients with mental illness
  16. Opinion Papers
  17. Fate of abstracts presented at the 2002 IFCC meeting
  18. Transition from congress abstract to full paper: the case of a national Argentinean congress in clinical laboratory
  19. Genetics and Molecular Diagnostics
  20. Association of endothelin-1 gene polymorphisms with variant angina in Korean patients
  21. Single nucleotide polymorphisms in ABCG5 and ABCG8 genes in Chilean subjects with polygenic hypercholesterolemia and controls
  22. Paternal exclusion: allele sharing in microsatellite testing
  23. General Clinical Chemistry
  24. Rapid sample preparation and simultaneous quantitation of prostaglandins and lipoxygenase derived fatty acid metabolites by liquid chromatography-mass spectrometry from small sample volumes
  25. Plasma bilirubin correlations in non-obstructive cholestasis after partial hepatectomy
  26. Aggregation of lipoprotein and inflammatory parameters in families with a history of premature myocardial infarction: the Tallinn Myocardial Infarction Study
  27. Significant elevation of a Th2 cytokine, interleukin-10, in pelvic inflammatory disease
  28. Hemoglobin A1c determination in the A1C-Derived Average Glucose (ADAG) study
  29. The effect of the mode of delivery on maternal-neonatal interleukin-6, biogenic amine and their precursor amino acid concentrations
  30. A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction
  31. Validation and Outcome Studies
  32. Benefits of the iQ200 automated urine microscopy analyser in routine urinalysis
  33. Electrochemical detection of blood alcohol concentration using a disposable biosensor based on screen-printed electrode modified with Nafion and gold nanoparticles
  34. About the z-multiplier in total error calculations
  35. Letters to the Editor
  36. A hypothyroid patient with increased free thyroid hormones
  37. Evaluation of blood collection tubes specific for homocysteine measurement
  38. Influence of assay-dependent variability of serum insulin levels on insulin sensitivity indices
  39. Frequency and type of preanalytical errors in a laboratory medicine department in India
  40. Sample dilution causes a positive bias on C-reactive protein using VITROS reagents, diluents and instruments – clinical implications?
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2008.295/html
Scroll to top button